Chad Cherington, MD
Hematology & Oncology · Mesa, AZNPI 1285952390
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.2%), consulting fees and education — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.7%.
Across 1,170 payments — averaging $30.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$3K
- Global Blood Therapeutics, Inc.$3K
- Kyowa Kirin, Inc.$3K
- Springworks Therapeutics, Inc.$2K
- Servier Pharmaceuticals LLC$2K
- AVEO Pharmaceuticals, Inc.$2K
- plus $22K from 54 others
Across 8 payments — averaging $93,164 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$608K
- Pfizer$137K
What the payments were for
- Consulting fees$13,47737%
- Speaking & faculty fees$1,1803%
- Food & beverage$20,31156%
- Education$1,1923%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,160 in reported general payments places this provider in the 85th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 22 | $414,287 |
| NubeqaDarolutamide | 27 | $331,105 |
| ErleadaApalutamide | 19 | $286,136 |
| JakafiRuxolitinib Phosphate | 14 | $258,056 |
| PomalystPomalidomide | 11 | $255,033 |
| BrukinsaZanubrutinib | 30 | $237,305 |
| BesremiRopeginterferon Alfa-2b-Njft | 13 | $109,845 |
| VenclextaVenetoclax | 17 | $82,650 |
| OrgovyxRelugolix | 26 | $69,777 |
| EliquisApixaban | 43 | $51,562 |
| Abiraterone Acetate | 42 | $47,508 |
| XareltoRivaroxaban | 55 | $46,273 |
| Hydroxyurea | 51 | $1,770 |
| Fentanyl | 12 | $1,391 |
| Mycophenolate Mofetil | 18 | $1,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,037 | $414,28722 claims |
| Johnson & JohnsonErleada, Xarelto | $1,384 | $332,40974 claims |
| BayerNubeqa | $3,150 | $331,10527 claims |
| Incyte CorporationJakafi | $308 | $258,05614 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $971 | $255,03311 claims |
| Beigene USA, Inc.Brukinsa | $50 | $237,30530 claims |
| AbbVieVenclexta | $525 | $82,65017 claims |
| PfizerEliquis | $1,076 | $51,56243 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $84 | $47,50842 claims |
| Boehringer IngelheimPradaxa | $57 | $41211 claims |
| Lilly USA, LLCOlanzapine | $238 | $29612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Mesa
- Pranshu BansalMesa$190K
- Neel DhariaMesa$134K
- Anu BatraMesa$30K
- Sujith KalmadiChandler$1.4M
- Jeffrey SchriberScottsdale$715K
- Javier MunozPhoenix$638K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Sumit MadanGilbert$422K
- Christopher ChenTucson$370K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.